open access

Vol 70, No 1 (2019)
TROPICAL MEDICINE Short communication
Published online: 2019-03-28
Submitted: 2019-03-02
Accepted: 2019-03-12
Get Citation

Malaria vaccine for travellers — where are we now?

Anna Kuna, Michał Gajewski
DOI: 10.5603/IMH.2019.0010
·
Pubmed: 30931520
·
International Maritime Health 2019;70(1):65-67.

open access

Vol 70, No 1 (2019)
TROPICAL MEDICINE Short communication
Published online: 2019-03-28
Submitted: 2019-03-02
Accepted: 2019-03-12

Abstract

The authors present a short summary of the current state of malaria vaccine development and the per- spectives for the availability of a malaria vaccines for travellers from non-endemic countries. There is currently no commercially available malaria vaccine for travellers. The efficacy of the RTS,S/AS01 vaccine is limited and differs dramatically from the effects of other vaccines administered in travel medicine. In the current recommendations, the use of repellents is deemed the most important measure to prevent malaria infection, and in the high-risk destinations, chemoprophylaxis is strongly advised. Many questions in malaria vaccinology remain unanswered. 

Abstract

The authors present a short summary of the current state of malaria vaccine development and the per- spectives for the availability of a malaria vaccines for travellers from non-endemic countries. There is currently no commercially available malaria vaccine for travellers. The efficacy of the RTS,S/AS01 vaccine is limited and differs dramatically from the effects of other vaccines administered in travel medicine. In the current recommendations, the use of repellents is deemed the most important measure to prevent malaria infection, and in the high-risk destinations, chemoprophylaxis is strongly advised. Many questions in malaria vaccinology remain unanswered. 

Get Citation

Keywords

malaria; communicable disease control; protozoan vaccines; travel-related illness

About this article
Title

Malaria vaccine for travellers — where are we now?

Journal

International Maritime Health

Issue

Vol 70, No 1 (2019)

Pages

65-67

Published online

2019-03-28

DOI

10.5603/IMH.2019.0010

Pubmed

30931520

Bibliographic record

International Maritime Health 2019;70(1):65-67.

Keywords

malaria
communicable disease control
protozoan vaccines
travel-related illness

Authors

Anna Kuna
Michał Gajewski

References (15)
  1. Arévalo-Herrera M, Vásquez-Jiménez JM, Lopez-Perez M, et al. Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial. PLoS Negl Trop Dis. 2016; 10(10): e0005070.
  2. World Health Organization. Malaria vaccine: WHO position paper, January 2016 - Recommendations. Vaccine. 2018; 36(25): 3576–3577.
  3. World Health Organization. World Malaria Report 2018. Geneva: World Health Organization. 2018.
  4. World Health Organization. Health and the millennium development goals. Geneva, Switzerland: World Health Organization; 2005.
  5. World Health Organization. Global Malaria Programme. Global technical strategy for malaria, 2016-2030. Geneva, Switzerland: Global Malaria Programme, World Health Organization. 2015.
  6. Greenwood B, Dicko A, Sagara I, et al. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malar J. 2017; 16(1): 182.
  7. Coelho CH, Doritchamou JY, Zaidi I, et al. Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. NPJ Vaccines. 2017; 2: 34.
  8. World Health Organization. Tables of malaria vaccine projects globally «The Rainbow Tables» 2015 2015. http://www.who.int/immunization/research/development/Rainbow_tables/en/. (cited 2016 January 1, 2016).
  9. Draper SJ, Sack BK, King CR, et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe. 2018; 24(1): 43–56.
  10. Ewer KJ, O'Hara GA, Duncan CJA, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013; 4: 2836.
  11. Mullard A. EMA approves first ever malaria vaccine. Nat Rev Drug Discov. 2015; 14(9): 593.
  12. Olotu A, Fegan G, Wambua J, et al. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med. 2016; 374(26): 2519–2529.
  13. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013; 368(12): 1111–1120.
  14. World Health Organization. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--recommendations. Vaccine. 2015; 33(1): 76–77.
  15. CDC CDC. Yellow Book 2018: Health Information for International Travel. New York: Oxford University Press. 2017.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl